阻塞性睡眠呼吸暂停患者围术期麻醉管理专家共识(2020修订版)快捷版

2021-02-20 中华医学会麻醉学分会 临床麻醉学杂志.2021.37(2):196-199.

阻塞性睡眠呼吸暂停( obstructive sleep apnea,OSA) 指患者睡眠时周期性地出现部分或完全的上呼吸道梗阻,以呼吸暂停和低通气为特征的疾病。我国成人OSA 总患病率为3.93%,

中文标题:

阻塞性睡眠呼吸暂停患者围术期麻醉管理专家共识(2020修订版)快捷版

发布日期:

2021-02-20

简要介绍:

阻塞性睡眠呼吸暂停( obstructive sleep apnea,OSA) 指患者睡眠时周期性地出现部分或完全的上呼吸道梗阻,以呼吸暂停和低通气为特征的疾病。我国成人OSA 总患病率为3.93%,男性为女性的2. 62 倍,但临床诊断率较低。合并OSA 的患者围术期并发症显著增多,死亡率显著增高,该类患者均应被列为麻醉的高危患者。为此,在2014 年ASA 阻塞性睡眠呼吸暂停患者的围术期管理威廉亚洲博彩公司 的基础上,参考国内外最新威廉亚洲博彩公司 及文献,重点对OSA 患者的术前筛查与诊断、危险因素、气道管理、麻醉用药等予以修订,以提高对OSA 患者围术期麻醉安全管理。

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1003285, encodeId=69951003285fe, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59961449622, createdName=254160703, createdTime=Wed Jul 28 11:34:16 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969746, encodeId=c7ae969e4629, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Mon May 31 00:53:21 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962540, encodeId=644a962540a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Tue May 04 05:59:19 CST 2021, time=2021-05-04, status=1, ipAttribution=)]
    2021-07-28 254160703

    学习了,谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1003285, encodeId=69951003285fe, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59961449622, createdName=254160703, createdTime=Wed Jul 28 11:34:16 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969746, encodeId=c7ae969e4629, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Mon May 31 00:53:21 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962540, encodeId=644a962540a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Tue May 04 05:59:19 CST 2021, time=2021-05-04, status=1, ipAttribution=)]
    2021-05-31 1477308bm10(暂无昵称)

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1003285, encodeId=69951003285fe, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59961449622, createdName=254160703, createdTime=Wed Jul 28 11:34:16 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969746, encodeId=c7ae969e4629, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Mon May 31 00:53:21 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962540, encodeId=644a962540a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Tue May 04 05:59:19 CST 2021, time=2021-05-04, status=1, ipAttribution=)]
    2021-05-04 我是谁是我

    学习了

    0

拓展阅读

2010 阻塞性睡眠呼吸暂停与糖尿病专家共识

中华医学会呼吸病学分会 · 2010-05-01

2012 AAP儿童阻塞性睡眠呼吸暂停综合征的诊断与治疗威廉亚洲博彩公司

美国儿科学会(AAP,American Academy of Pediatrics) · 2012-08-27

2012 SAMBA共识:成人阻塞性睡眠呼吸暂停患者接受门诊手术的术前选择

门诊麻醉学会(SAMBA,The Society for Ambulatory Anesthesia) · 2012-11-01

2013 ERS/ESH 阻塞性睡眠呼吸暂停与高血压患者管理建议

欧洲呼吸学会(ERS,European Respiratory Society) · 2013-05-01